New drug combo aims to fight resistant lung cancer

NCT ID NCT05009836

Ongoing Disease control Sponsor: Hutchison Medipharma Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether adding savolitinib to the standard drug osimertinib helps people with a specific type of advanced lung cancer (EGFR-mutant, MET-positive non-small cell lung cancer). About 412 participants will receive either the combination or a placebo plus osimertinib. The study measures how long the cancer stays under control and checks for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: savolitinib combined with osimertinib
What this could lead to: If successful, this combination could become a new first-line treatment option for people with a specific type of lung cancer, potentially delaying disease progression.
What could go wrong: This is a phase 3 trial, but results are not yet available. The combination may not improve outcomes over standard care and could cause additional side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Guangdong General Hospital

Guangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.